Dutch company Enzyre has raised $11.85m (€12m) in a Series A financing round to accelerate the development of its ambulant diagnostic technology platform for haemophilia patients.
Led by new investor Oost NL, the financing round also saw participation from Demcon Investment and i&i Biotech Fund along with existing investors Novalis Biotech and Takeda Ventures.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Enzyre also said that a part of the funding comes from an innovation credit from the Dutch Government.
The company intends to use the funds for further development of EnzyPad, its diagnostic technology platform that allows haemophilia patients to discover and monitor their coagulation status at home.
The proceeds will also support clinical trial registrations, the establishment of manufacturing capabilities, and investment to further expand the platform’s applications in critical care settings.
Enzyre’s Hemophilia EnzyCard uses the EnzyPad platform technology to determine the coagulation status of haemophilia patients.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataIt is intended to help haemophilia patients self-test their coagulation status and share the results with their physicians using a cloud-based application and mobile phone app.
The platform uses a small volume of blood and can measure up to 16 reactions simultaneously.
Enzyre CEO Guido Maertens said: “We are delighted to have closed this successful financing round, which validates our technology and will underpin our ongoing development as we take Enzyre forward into the next phase of growth.
“We value Takeda’s continued support and welcome the commitment from a strong cohort of new and existing investors.
“Together we look forward to improving the quality of life for patients living with bleeding disorders by driving forward our goal to transform their standard of care.”
